This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clemons, K. V. Articles by Stevens, D. A. Search for Related Content PubMed PubMed Citation Articles by Clemons, K. V. Articles by Stevens, D. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2420-2426, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2420-2426.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Efficacy of Intravenous Liposomal Amphotericin B (AmBisome) against Coccidioidal Meningitis in Rabbits

Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center,¹ California Institute for Medical Research, San Jose, California 95128,² Department of Medicine, Division of Infectious Diseases and Geographic Medicine,³ Department of Pathology, Stanford University, Stanford, California 94305,⁴ Palo Alto Veterans Affairs Health Care System, Palo Alto, California 94304,⁵ Kaweah Delta District Hospital, Visalia, California 93291,⁶ Department of Medical Microbiology and Immunology, School of Medicine, University of California at Davis, Davis, California 95616⁷

Received 29 April 2002/ Accepted 1 May 2002

The efficacy of intravenously administered liposomal amphotericin B (AmBisome [AmBi]) for the treatment of experimental coccidioidal meningitis was compared with those of oral fluconazole (FLC) and intravenously administered conventional amphotericin B (AMB). Male New Zealand White rabbits were infected by intracisternal inoculation of arthroconidia of Coccidioides immitis. Starting 5 days postinfection, animals received one of the following: 5% dextrose water diluent; AMB given at 1 mg/kg of body weight; AmBi given at 7.5, 15, or 22.5 mg/kg intravenously three times per week for 3 weeks; or oral FLC given at 80 mg/kg for 19 days. One week after the cessation of therapy, all survivors were euthanatized, the numbers of CFU remaining in the spinal cord and brain were determined, and histological analyses were performed. All AmBi-, FLC-, or AMB-treated animals survived and had prolonged lengths of survival compared with those for the controls (P < 0.0001). Treated groups had significantly lower numbers of white blood cells and significantly lower protein concentrations in the cerebrospinal fluid compared with those for the controls (P < 0.01 to 0.0005) and had fewer clinical signs of infection (e.g., weight loss, elevated temperature, and neurological abnormalities including motor abnormalities). The mean histological scores for AmBi-treated rabbits were lower than those for FLC-treated and control rabbits (P < 0.016 and 0.0005, respectively); the scores for AMB-treated animals were lower than those for the controls (P < 0.0005) but were similar to those for FLC-treated rabbits. All regimens reduced the numbers of CFU in the brain and spinal cord compared with those for the controls (P 0.0005). AmBi-treated animals had 3- to 11-fold lower numbers of CFU than FLC-treated rabbits and 6- to 35-fold lower numbers of CFU than AmB-treated rabbits. Three of eight animals given 15 mg of AmBi per kg had no detectable infection in either tissue, whereas other doses of AmBi or FLC cleared either the brain or the spinal cord of infection in fewer rabbits. In addition, clearance of the infection from both tissues was achieved in none of the rabbits, and neither tissue was cleared of infection in AMB-treated animals. Overall, these data indicate that intravenously administered AmBi is superior to oral FLC or intravenous AMB and that FLC is better than AMB against experimental coccidioidal meningitis. These data indicate that AmBi may offer an improvement in the treatment of coccidioidal meningitis. Additional studies are warranted.

This article has been cited by other articles:

• Olson, J. A., Adler-Moore, J. P., Jensen, G. M., Schwartz, J., Dignani, M. C., Proffitt, R. T. (2008). Comparison of the Physicochemical, Antifungal, and Toxic Properties of Two Liposomal Amphotericin B Products. Antimicrob. Agents Chemother. 52: 259-268 [Abstract] [Full Text]  
• Capilla, J., Clemons, K. V., Sobel, R. A., Stevens, D. A. (2007). Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother 60: 673-676 [Abstract] [Full Text]  
• Olson, J. A., Adler-Moore, J. P., Schwartz, J., Jensen, G. M., Proffitt, R. T. (2006). Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.. Antimicrob. Agents Chemother. 50: 2122-2131 [Abstract] [Full Text]  
• Andes, D., Safdar, N., Marchillo, K., Conklin, R. (2006). Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models. Antimicrob. Agents Chemother. 50: 674-684 [Abstract] [Full Text]  
• Clemons, K. V., Espiritu, M., Parmar, R., Stevens, D. A. (2005). Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis. Antimicrob. Agents Chemother. 49: 4867-4875 [Abstract] [Full Text]  
• Olson, J. A., Adler-Moore, J. P., Smith, P. J., Proffitt, R. T. (2005). Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin. Antimicrob. Agents Chemother. 49: 4895-4902 [Abstract] [Full Text]  
• Adler-Moore, J. P., Olson, J. A., Proffitt, R. T. (2004). Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 54: 1096-1102 [Abstract] [Full Text]  
• Hsue, G., Napier, J. T., Prince, R. A., Chi, J., Hospenthal, D. R. (2004). Treatment of meningeal coccidioidomycosis with caspofungin. J Antimicrob Chemother 54: 292-294 [Full Text]